DUBLIN, June 19, 2017 /PRNewswire/ -- Perrigo
Company plc (NYSE; TASE: PRGO) today announced it has launched
hydrocodone bitartrate and homatropine methylbromide oral solution.
Hydrocodone bitartrate and homatropine methylbromide oral solution
was formerly marketed under the trade name Hycodan® by
Endo Pharmaceuticals Inc.
Hydrocodone bitartrate and homatropine methylbromide oral
solution is indicated for the symptomatic relief of cough in adults
and children 6 years of age and older. Annual market sales for the
12 months ending April 2017 were
approximately $15 million.
Perrigo CEO John T. Hendrickson
stated, "This launch is another example of Perrigo's ongoing
commitment to developing quality, high value alternatives in the
cough and cold treatment category. As we continue to deliver on our
mission of providing Quality Affordable Healthcare
Products®, the Rx team expects to launch two
more products by the end of this month and more than five products
by the end of the calendar year."
About Perrigo
Perrigo Company plc, a leading global healthcare company,
delivers value to its customers and consumers by
providing Quality Affordable Healthcare Products®.
Founded in 1887 as a packager of home remedies, Perrigo has built a
unique business model that is best described as the convergence of
a fast-moving consumer goods company, a high-quality pharmaceutical
manufacturing organization and a world-class supply chain network.
Perrigo is the world's largest manufacturer of over-the-counter
("OTC") healthcare products and supplier of infant formulas for the
store brand market. The Company also is a leading provider of
branded OTC products throughout Europe and the U.S., as
well as a leading producer of "extended topical" prescription
drugs. Perrigo, headquartered in Ireland, sells its products
primarily in North America and Europe, as well as in
other markets,
including Australia, Israel and China. Visit
Perrigo online at (http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the timing, amount and cost of any
share repurchases; future impairment charges; customer acceptance
of new products; competition from other industry participants, some
of whom have greater marketing resources or larger market shares in
certain product categories than we do; pricing pressures from
customers and consumers; potential third-party claims and
litigation, including litigation relating to our restatement of
previously-filed financial information; potential impacts of
ongoing or future government investigations and regulatory
initiatives; general economic conditions; fluctuations in currency
exchange rates and interest rates; the consummation of announced
acquisitions or dispositions, and our ability to realize the
desired benefits thereof; our ability to achieve our guidance; our
ability to execute and achieve the desired benefits of announced
cost-reduction efforts and other initiatives; and the timing and
expense to complete the announced tender offer for certain of our
outstanding notes. In addition, the Company may identify and
be unable to remediate one or more material weaknesses in its
internal control over financial reporting. Furthermore, the Company
and/or its subsidiaries may incur additional tax liabilities in
respect of 2016 and prior years as a result of any restatement or
may be found to have breached certain provisions of Irish company
legislation in respect of prior financial statements and if so may
incur additional expenses and penalties. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-K for the year ended December 31, 2016, as
well as the Company's subsequent filings with the United States
Securities and Exchange Commission, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-the-launch-of-hydrocodone-bitartrate-and-homatropine-methylbromide-oral-solution-300475775.html
SOURCE Perrigo Company plc